Jubilant Therapeutics Inc, a biopharmaceutical company, has collaborated with Boston Children's Hospital to assess peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics, it was reported on Thursday.
The study is intended to explore the modulation of neutrophil extracellular traps (NETs)in preclinical models of neutrophil regulation and rheumatoid arthritis (RA). PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS.
Syed Kazmi, president and CEO of Jubilant Therapeutics, said, 'We are pleased to announce our collaboration with Boston Children's Hospital, whose reputation as the nation's leading paediatric hospital and research enterprise make them an ideal partner as we endeavour to develop the next generation of therapeutics for autoimmune diseases. Dr Denisa Wagner, the lead investigator, has extensive experience both in the PAD4 space and the role of NETs in pathological inflammation, and we're thrilled to have her on the team.'
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007